gliptin; dipeptidyl peptidase-4 inhibitor; DPP-4 inhibitor

From Aaushi
Jump to navigation Jump to search

Indications

Dosage adjustment in renal failure

Adverse effects

* unfavorable adverse effect profile including anaphylaxis & pancreatitis[13]

Drug interactions

* associated with decreased risk for hypoglycemia (RR = 0.86)[9]

* associated with increased risk for hypoglycemia (absolute risk 12% vs 7% for sulfonylurea alone[10]

Mechanism of action

Clinical trials

Notes

More general terms

More specific terms

Additional terms

References

  1. Prescriber's Letter 12(9): 2005 Investigational Medicines for Diabetes: Sitagliptan (Januvia) and Vildagliptan (Galvus) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220715&pb=PRL (subscription needed) http://www.prescribersletter.com
  2. Prescriber's Letter 13(11): 2006 New Drug: Sitagliptin (Januvia) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=221102&pb=PRL (subscription needed) http://www.prescribersletter.com
  3. 3.0 3.1 3.2 3.3 Karagiannis T et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: Systematic review and meta-analysis. BMJ 2012 Mar 12; 344:e1369 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22411919
  4. 4.0 4.1 Prescriber's Letter 19(6): 2012 CHART: Drugs for Type 2 Diabetes ALGORITHM: Stepwise Approach to Selecting Treatments for Type 2 Diabetes (ADA) GUIDELINES: Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach (2012) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=280614&pb=PRL (subscription needed) http://www.prescribersletter.com
  5. 5.0 5.1 Singh S et al Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus. A Population-Based Matched Case-Control Study. JAMA Intern Med. 2013;():1-6. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23440284 <Internet> http://archinte.jamanetwork.com/article.aspx?articleid=1656537
  6. FDA MedWatch. August 28, 2015 DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm460238.htm
  7. 7.0 7.1 7.2 7.3 7.4 7.5 7.6 Medical Knowledge Self Assessment Program (MKSAP) 17, 18, American College of Physicians, Philadelphia 2015, 2018.
  8. 8.0 8.1 Li L, Li S, Deng K et al Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ 2016;352:i610 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26888822 Free full text <Internet> http://www.bmj.com/content/352/bmj.i610
  9. 9.0 9.1 Hippisley-Cox J, Coupland C Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care. BMJ 2016;352:i1450 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27029547 <Internet> http://www.bmj.com/content/352/bmj.i1450
    Montori VM Selecting the right drug treatment for adults with type 2 diabetes. BMJ 2016;352:i1663 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27029501 <Internet> http://www.bmj.com/content/352/bmj.i1663
  10. 10.0 10.1 Salvo F et al Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. BMJ 2016;353:i2231 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27142267 Free full text <Internet> http://www.bmj.com/content/353/bmj.i2231
  11. 11.0 11.1 Tkac I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care 2017 Feb; 40:284. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27659407 <Internet> http://care.diabetesjournals.org/content/40/2/284
    DeVries JH, Rosenstock J. DPP-4 inhibitor-related pancreatitis: Rare but real! Diabetes Care 2017 Feb; 40:161 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28108536 <Internet> http://care.diabetesjournals.org/content/40/2/161
  12. 12.0 12.1 Liu J, Li L, Deng K et al Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ. 2017 Jun 8;357:j2499. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28596247 Free PMC Article
  13. 13.0 13.1 13.2 13.3 Therapeutics Letter #108. Therapeutics Initiative Drugs to Avoid. http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/
  14. 14.0 14.1 Abrahami D, Douros A, Yin H, et al Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 2018;360:k872 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29563098 <Internet> http://www.bmj.com/content/360/bmj.k872
  15. 15.0 15.1 Abrahami D, Douros A, Yin H et al Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ 2018;363:k4880 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30518618 https://www.bmj.com/content/363/bmj.k4880
  16. 16.0 16.1 16.2 Lee M et al. Nationwide trends in pancreatitis and pancreatic cancer risk among patients with newly diagnosed type 2 diabetes receiving dipeptidyl peptidase 4 inhibitors. Diabetes Care 2019 Nov; 42:2057 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31431452 https://care.diabetesjournals.org/content/42/11/2057
  17. 17.0 17.1 Geriatric Review Syllabus, 10th edition (GRS10) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2019
  18. 18.0 18.1 18.2 George J Diabetes Drug Linked With Less Brain Amyloid. People with diabetes on DPP-4 inhibitors also showed slower cognitive decline. MedPage Today August 11, 2021 https://www.medpagetoday.com/neurology/alzheimersdisease/93999
    Jeong SH, Kim HR, Kim J et al Association of dipeptidyl peptidase-4 inhibitor use and amyloid burden in diabetic patients with AD-related cognitive impairment. Neurology 2021. Aug 11. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34380754 https://n.neurology.org/content/early/2021/08/11/WNL.0000000000012534
  19. 19.0 19.1 NEJM Knowledge+ Endocrinology